Navigation Links
SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease
Date:5/3/2011

with the regulatory bodies to facilitate a smooth path towards approval."

"It is well known that dry eye disease can have a deleterious effect on visual function, daily activities, workplace productivity, and quality of life. The potential to impact a patient's quality of life in as early as 2 weeks could be a major advance in the current dry eye treatment model," said Quinton Oswald, Chief Executive Officer of SARcode Corporation. "We hope to achieve similar results in our Phase 3 program."

About Dry Eye Syndrome

Dry eye syndrome is a prevalent and often chronic condition estimated to affect approximately 20 million people in the US. It is among the most common diseases treated by ophthalmologists throughout the world, and has been shown to have a significant impact upon quality of life. Dry eye varies in severity and etiology, and symptoms most commonly manifest as discomfort, visual disturbances, and tear film instability due to decreased quality or quantity of tears. A major contributing factor towards the development of dry eye is inflammation caused by T-cell infiltration, proliferation and inflammatory cytokine production that can lead to reduction in tear film quality and ocular surface damage.

About SAR 1118

SAR 1118 is a potent novel small molecule lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; alphaLbeta2) antagonist under investigation for a broad range of ocular inflammatory conditions including dry eye and diabetic macular edema. LFA-1 is member of the integrin family of adhesion receptors found on the surface of all leukocytes and represents a therapeutic target central to a number of inflammatory stimuli. SAR 1118 has demonstrated potency in blocking LFA-1 binding to its cognate ligand, intercellular adhesion molecule-1 (ICAM-1; CD54), thereby inhibiting cell adhesion, cytokine production, and cellular proliferation in in vitro models.

About SARcode Corpora
'/>"/>

SOURCE SARcode Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Baxa Corporation Demonstrates End-to-End Environmental Stewardship
2. REMEDIAL II Trial of PLCs RenalGuard® Demonstrates Greater Efficacy than Current Standard of Care
3. Publication in SLEEP Journal Demonstrates Positive Results of Large Multi-Center Clinical Trial for Provent® Sleep Apnea Therapy
4. Siemens Demonstrates Strategy for Sustainable Cardiovascular Care
5. Boston Scientific ION™ Platinum Chromium Stent System Demonstrates Strong Performance in Analysis of PERSEUS and TAXUS ATLAS Clinical Trial Data
6. Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies
7. OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status
8. S*BIOs Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
9. Allscripts Demonstrates Native Integration of Acute and Ambulatory Electronic Health Records at HIMSS
10. Recent Study Demonstrates Anti-Inflammatory Properties of Oligonol® Lychee Fruit Polyphenols in Humans
11. Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... SAN FRANCISCO , May 5, 2015 ... a Small Business Innovation Research (SBIR) grant from the ... Creek is a San Francisco ... therapeutics to selectively repair tissues damaged by disease. This ... therapeutics engineered to repair heart tissue following a heart ...
(Date:5/5/2015)... , May 5, 2015 Ardelyx, Inc. ... focused on cardio-renal, gastrointestinal, and metabolic diseases, today ... evaluating tenapanor in Stage 3 chronic kidney disease ... did not meet the primary endpoint of decreasing ... to patients receiving placebo. Ardelyx ...
(Date:5/5/2015)... , May 5, 2015 North ... $94.9 million in 2014, and is estimated to grow ... 7.8% from 2014 to 2019. Browse through ... Market for an analysis of industry trends and segments, ... http://www.micromarketmonitor.com/market/north-america-glaucoma-surgery-devices-8830146604.html Early buyers ...
Breaking Medicine Technology:Silver Creek Pharmaceuticals Awarded NIH SBIR Grant for Smart Growth Factor Technology 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 2North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 3
... Further,Scientific Validation of the Potential Utility of Modigene,s CTP Technology ... ... -, VIENNA, Va., Sept. 24 Modigene Inc. (OTC,Bulletin Board: ... edition of the journal Endocrinology showing that,erythropoietin (EPO) linked to Modigene,s ...
... FRAMINGHAM, Mass., Sept. 24 Iodine has been ... has been written about molecular,iodine yet many women ... studies being conducted may soon yield an effective,nonhormonal ... drugs on the market, all,available hormonal therapies have ...
Cached Medicine Technology:Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 2Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 3Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 4Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease 2
(Date:5/5/2015)... 05, 2015 Carlini CPA, PLLC is ... Matthews, Charlotte and surrounding areas. The company has over ... This company provides assistance in making informed decisions about ... individual or corporate tax returns for their clients. ... that allows clients (and Carlini CPA) to pass documents ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Horizon Blue ... its strong and secure credit rating of “A” from ... BCBSNJ’s financials last week, the Wall Street ratings agency ... “leading market position” in determining the rating and “stable” ... is one of our top priorities, so we are ...
(Date:5/5/2015)... The 2015 Crystal Ball, hosted by the Hepatitis ... outreach and patient advocacy programs. The gala evening included dancing, ... hundreds of supporters. , The 2015 gala was dedicated to ... virus (HBV) by Dr. Baruch S. Blumberg, who passed away ... for his discovery of the virus in 1976. He and ...
(Date:5/5/2015)... New York, NY (PRWEB) May 05, 2015 The ... based on the experiences of Dr. Brad Reedy from ... When Judith Regan was asked why she chose to publish a ... me as a parent (and publisher) is the idea that it ... question...that we and our children are on the trek sometimes together ...
(Date:5/5/2015)... Los Angeles, CA (PRWEB) May 05, 2015 ... to treat and actually prevent a variety of health ... Doc utilized this modern research to adopt clean eating ... preservatives and artificial dyes associated with over-consumption of fast ... eating diet plans easy to follow and report ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Maintains “A” Credit Rating from Standard & Poor’s 2Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 2Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 3Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 2Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 3Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 2Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 3
... Equip for Equality Obtains Federal Injunction Against the State ... 30 Following two years of,federal court litigation under ... permanent injunction to enable its client, David,Grooms, to receive ... order,overturned a decision by the Illinois Department of Healthcare ...
... as fact , , MONDAY, June 30 (HealthDay News) -- A new ... and loss of memory. , The study, which has followed thousands ... loss of memory on a word test for those at age ... highest levels. By age 60, the rate of memory loss had ...
... 20 percent of people worldwide suffer from migraines ... By studying a rare, inherited form of migraine, researchers ... the biological basis of the painful, debilitating disorder. , ... Sciences, Alfred George Jr., M.D., and colleagues report ...
... Backyard barbecues and beach bonfires are beloved summer activities ... especially children at risk of painful, long-term injury. ... Center director, urges extra caution with the use and ... at campsites. "We,re seeing approximately two dozen firepit injuries ...
... June 30 As heat waves plague much of,the United ... director,for the famed nonprofit Los Angeles Jewish Home -- one ... Angeles -- has,offered tips for the nation,s elderly to avoid ... United States, about 200 people die of health problems,caused by ...
... to be included as part of company,s, comprehensive Pressure Ulcer ... ... pressure ulcers, MUNDELEIN, Ill., June 30 Medline Industries, ... room table pads and stretcher pads aimed at helping,hospitals and ...
Cached Medicine News:Health News:Young Man With Severe Disabilities Wins Right to Services From State Enabling Him to Live At Home 2Health News:Young Man With Severe Disabilities Wins Right to Services From State Enabling Him to Live At Home 3Health News:Research Links Low HDL Levels With Memory Loss 2Health News:Migraine mutations reveal clues to biological basis of disorder 2Health News:From beach to backyard, caution can reduce firepit burns 2Health News:Medical Director for Renowned Los Angeles Jewish Home Offers Top Tips to Elderly in Coping With Searing Temperatures Across U.S. 2Health News:Medical Director for Renowned Los Angeles Jewish Home Offers Top Tips to Elderly in Coping With Searing Temperatures Across U.S. 3Health News:Medline Announces Advanced Line of Therapeutic Mattresses, Operating Room Table Pads and Stretcher Pads 2Health News:Medline Announces Advanced Line of Therapeutic Mattresses, Operating Room Table Pads and Stretcher Pads 3
Langenbeck periosteal elevators, wide, blade width 11/16" (17 mm), length 7 1/2" (191 mm)....
Cushing periosteal elevators, Gutsch handle, sharp, narrow, blade width 3/16" (5 mm), length 7 5/8" (194 mm)....
Lederer periosteal elevators....
Miller Collburn periosteal elevators....
Medicine Products: